ASH 2025 | Three-year follow-up from S1826: immunotherapy plus combination chemotherapy in stage III-IV cHL

S1826 was a randomized Phase III study of adults or adolescents with stage 3 or 4 classic Hodgkin lymphoma. It was a randomized Phase III study randomizing patients in a one-to-one fashion to receive either nivolumab-AVD or brentuximab vedotin-AVD for six cycles. What we demonstrated this year was that with three years of follow-up, the advantage that we saw from a progression-free survival when nivolumab-AVD was sustained and patients treated with nivolumab-AVD had a three-year progression-free survival of 91% compared to 82% of patients treated with brentuximab vedotin-AVD. Now, importantly, the advantage that we saw from a PFS perspective in nivolumab-AVD was consistent across pre-specified subgroups. So across all the different age subgroups, adolescents under the age of 18, adults ages 18 to 60, or older adults over the age of 60. We also saw that nivolumab-AVD improved progression-free survival in patients with low IPS scores or high international prognostic scores. We saw that nivolumab-AVD led to prolonged progression-free survival in patients with stage 3 disease or stage 4 disease. And the other analysis that we performed was we looked at secondary cancers. It’s still relatively short follow-up with three years of follow-up, but at this point, you know, there have been a very low rate of second cancers, and there have been no secondary myeloid neoplasms to date. So overall, our three-year update of S1826 demonstrated that the prolonged progression-free survival that we observed with nivolumab-AVD persisted, and we identified high-risk subgroups of interest where nivolumab-AVD did prolong progression-free survival in, and indeed across all subgroups that we analyzed, nivolumab-AVD performed better than brentuximab vedotin-AVD.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.